Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TARBP2 | Q15633 | 7/20 | 0.60 |
| ▸ | PDCD4 | Q53EL6 | 1/20 | 0.51 |
| ▸ | FBP1 | P09467 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | XBP1 | P17861 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | GLP1R | P43220 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26984667 | 0.83 | TARBP2 (0.53) | TARBP2PDCD4FBP1ALDH1A1HSD17B10 | |
| SCHEMBL2616840 | 0.81 | TARBP2 (0.58) | TARBP2PDCD4FBP1ALDH1A1HSD17B10 | |
| SCHEMBL26984654 | 0.80 | TARBP2 (0.45) | TARBP2PDCD4FBP1ALDH1A1HSD17B10 | |
| SCHEMBL26990023 | 0.80 | FBP1 (0.50) | TARBP2PDCD4FBP1ALDH1A1HSD17B10 | |
| SCHEMBL18039552 | 0.79 | TARBP2 (0.60) | TARBP2PDCD4FBP1ALDH1A1HSD17B10 | |
| SCHEMBL17714563 | 0.79 | FBP1 (0.69) | TARBP2PDCD4FBP1ALDH1A1MAPT | |
| SCHEMBL26984501 | 0.78 | TARBP2 (0.43) | TARBP2PDCD4FBP1ALDH1A1HSD17B10 | |
| SCHEMBL26984708 | 0.78 | TARBP2 (0.43) | TARBP2PDCD4FBP1ALDH1A1HSD17B10 | |
| SCHEMBL26984582 | 0.77 | TARBP2 (0.42) | TARBP2PDCD4FBP1ALDH1A1HSD17B10 | |
| SCHEMBL19122947 | 0.76 | TARBP2 (0.52) | TARBP2PDCD4FBP1ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4551571-A1 | OXAZOLE TRPML1 AGONISTS AND USES THEREOF | Libra Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| CN-119790050-A | Oxazole TRPML1 agonists and uses thereof | 利布拉医疗公司 | 2025-04-08 | — | — | CN | disclosed |
| US-12098145-B2 | Oxazole TRPML1 agonists and uses thereof | LIBRA THERAPEUTICS, INC. (US) | 2024-09-24 | — | — | US | disclosed |
| US-20240158381-A1 | OXAZOLE TRPML1 AGONISTS AND USES THEREOF | LIBRA THERAPEUTICS, INC. | 2024-05-16 | — | — | US | disclosed |
| WO-2024011155-A1 | OXAZOLE TRPML1 AGONISTS AND USES THEREOF | LIBRA THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| WO-2024011155-A1 | OXAZOLE TRPML1 AGONISTS AND USES THEREOF | LIBRA THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| US-10435398-B2 | Oxazole orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2019-10-08 | — | — | US | disclosed |
| US-10435398-B2 | Oxazole orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2019-10-08 | — | — | US | disclosed |
| US-9987255-B2 | 5,5-bicyclic oxazole orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-06-05 | — | — | US | disclosed |
| US-9987255-B2 | 5,5-bicyclic oxazole orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-06-05 | — | — | US | disclosed |
| WO-2016069515-A1 | OXAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-05-06 | — | — | WO | disclosed |
| WO-2016065583-A1 | OXAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-05-06 | — | — | WO | disclosed |
| WO-2016065583-A1 | OXAZOLE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-05-06 | — | — | WO | disclosed |
| US-9233951-B2 | Heterocyclic compounds as pesticides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-01-12 | — | — | US | disclosed |
| WO-2015095111-A1 | DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015095111-A1 | DIAZEPANE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-06-25 | — | — | WO | disclosed |
| EP-2593447-A2 | NEW HETEROCYCLIC COMPOUNDS AS PESTICIDES | Bayer Intellectual Property GmbH (DE) | 2013-05-22 | — | — | EP | disclosed |
| US-20120094837-A1 | Novel Heterocyclic Compounds as Pesticides | BAYER CROP SCIENCE AG (DE) | 2012-04-19 | — | — | US | disclosed |
| WO-2012033195-A1 | HETEROCYCLIC COMPOUND | 京都薬品工業株式会社 (JP) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012007500-A2 | NEW HETEROCYCLIC COMPOUNDS AS PESTICIDES | BAYER CROPSCIENCE AG (DE) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10435398-B2 | Oxazole orexin receptor antagonists | HCRTR2, HCRTR1, OXTR | TARBP2 4670/4885PDCD4 1688/4885FBP1 2721/4885 |
| US-20120094837-A1 | Novel Heterocyclic Compounds as Pesticides | DDT, PTMS, ACHE | TARBP2 631/4885PDCD4 249/4885FBP1 1351/4885 |
| US-12098145-B2 | Oxazole TRPML1 agonists and uses thereof | TRPM7, TRPM2, TRPM5 | TARBP2 4206/4885PDCD4 2877/4885FBP1 2335/4885 |
| US-20240158381-A1 | OXAZOLE TRPML1 AGONISTS AND USES THEREOF | TRPM7, TRPM2, TRPM5 | TARBP2 4134/4885PDCD4 2799/4885FBP1 1695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.